¿ Creative BioMolecules Inc., of Hopkinton, Mass., entered into a research agreement with Neogenesis Inc., a privately held small-molecule drug discovery company, to identify orally available small molecules that mimic or induce tissue formation. The initial focus is on identifying lead compounds to treat chronic degenerative disorders. Terms were not disclosed.
¿ CytoTherapeutics Inc., of Lincoln, R.I., said its researchers and collaborators demonstrated, for the first time, that human neural stem/progenitor cells, transplanted into the brains of rats, migrated from the site of implantation and integrated into the host tissue. The ultimate goal of the research is to establish a bank of normal human neural cells for use in transplantation.
¿ Incyte Pharmaceuticals Inc., of Palo Alto, Calif., expanded and extended its genomics agreement with Genentech Inc., of South San Francisco, in a deal that gives Genentech access to Incyte's LifeSeq Gold assembled database. The agreement also includes Incyte's first partnering program in bioinformatics, whereby it will apply its large-scale data processing and information management capabilities for Genentech's discovery programs. Financial terms were not disclosed. Also, Incyte reported revenues of $37.9 million for the second quarter and a net loss of $7.4 million.
¿ InSite Vision Inc., of Alameda, Calif., signed a genetic research agreement in the area of glaucoma with Canadian Laval University in Quebec. The agreement covers the discovery of new genes and extends InSite's glaucoma mutation screening database to include Canadian residents.
¿ Sibia Neurosciences Inc., of La Jolla, Calif., entered into a non-exclusive licensing agreement with Pharmacia & Upjohn, of Bridgewater, N.J., for Sibia's transcription-based assay patent portfolio. Sibia will get annual maintenance payments and royalties on any compounds commercialized as a result of the technology.
¿ Valentis Inc., of Burlingame, Calif., said the date Eli Lilly & Co., of Indianapolis, may extend or terminate their gene therapy collaboration has been changed from May 1999 to Nov. 30, 1999, to allow completion of preclinical studies. Their May 1997 agreement is for development of gene therapies using the BRCA-1 gene to treat solid tumors, primarily breast and ovarian cancer. (See BioWorld Today, May 30, 1997, p. 1.)